Bringing New Horizons to Therapy


General News

Favourable long-term outcomes of Ablatherm HIFU published in European Urology

A recent in-press publication in European Urology reported long-term clinical outcomes of 803 patients treated with Ablatherm® HIFU between 1993 and 2007. This study conducted by Dr. Sébastien Crouzet, the control of the disease was achieved with an 85% rate of negative biopsies and a biochemical disease free survival rate (Phoenix criteria) of 83% in low risk cancer patients. The durability of efficacy outcomes of robotic Ablatherm-HIFU in the treatment of localized prostate cancer is now established out to eight years.

Print This Page